This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these messages)
|
Ambika Bumb | |
|---|---|
| | |
| Alma mater | University of Oxford (PhD) Georgia Institute of Technology (BME) |
| Occupations |
|
| Organization | Bikanta |
| Honors | Marshall Scholar |
Ambika Bumb is an American biomedical scientist and businessperson. [1] Bumb specializes in nanomedicine, utilizing nanotechnology for disease detection and treatment. As a postdoctoral researcher at the National Cancer Institute and the National Heart, Lung, and Blood Institute, Bumb made new discoveries with nanodiamonds which led to the launch of the biotech Bikanta. [2] [3] Bumb is currently the Deputy Executive Director at the Bipartisan Commission on Biodefense. [4]
Bumb was born to Indian Jain parents who immigrated to the United States in pursuit of higher education. Bumb graduated from Southside High School as valedictorian in 2002. [5]
Bumb graduated in 2005 with a Bachelor of Science in Biomedical Engineering and a Minor in Economics from Georgia Institute of Technology. During her undergraduate studies, Bumb received the Helen E. Grenga Outstanding Woman Engineer Award and the E. Jo Baker President's Scholar Award. [6] She researched tracking quantum dots in bone and cartilage. Additionally, she was an active leader in various campus organizations. [7]
In 2008, Bumb completed her Doctorate in Medical Engineering in three years from University of Oxford as a recipient of both the Marshall Scholarship and the NIH-OxCam Program. [8] [9] She developed a triple-reporting nanoparticle and showed the technology's transferability across different disease types, including cancer and multiple sclerosis. The magnetic nanoparticles demonstrated strong potential in cancer diagnostics and therapy. [8] [10] Upon graduation, she continued on to two post-doctoral fellowships at the National Cancer Institute (2009-2011) and National Heart, Lung and Blood Institute (2011-2013).[ citation needed ]
Her breakthroughs in the areas of nanomedicine and diagnostics have led to multiple patents, publications. Bumb also founded her own biotech company, Bikanta[ citation needed ], which uses nanodiamonds to allow academics and doctors to study and address disease at the cellular level. Bikanta was among the early biotechnology startups to receive funding from Y Combinator, and was a recipient of the California Life Science Institute's FAST Award, and named 1 of 4 Best Diagnostics Startups of 2015 by QB3. [11]
As Bikanta prepared to move the technology into clinical trials, the Theranos scandal went public and many investors pulled out of the diagnostics space. [12] Bikanta was unable to raise the funding to proceed with the clinical trials. [13]
Complementary to her scientific and commercial interests, Bumb has also been involved in national science policy initiatives, particularly related to nanotechnology. [14] After Bikanta, Bumb began working as Health Science and Technology Advisor for the Secretary of State in the Office of Crisis Management and Strategy in December 2019, where she played a role in the government response to the COVID-19 pandemic. [13] Later, she transferred to President Joe Biden's Council of Advisors on Science and Technology as Deputy Executive Director. [15] [4]
{{cite book}}: CS1 maint: multiple names: authors list (link)